DETRIMENTAL IMPACT OF TOXICITY ON QUALITY OF LIFE IN HEPATOCELLULAR CARCINOMA PATIENTS TREATED WITH LENVATINIBOR SORAFENIB

被引：1
|
作者：
Hudgens, S. [1 ]
Misurski, D. [2 ]
Meier, G. [2 ]
机构：
[1] Clin Outcomes Solut, Tucson, AZ USA
[2] Eisai Inc, Woodcliff Lake, NJ USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.084
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN2
引用
收藏
页码：A411 / A412
页数：2
相关论文
共 50 条
  • [21] Overall survival predictors in hepatocellular carcinoma patients treated with sorafenib
    da Costa Ferreira, Caroline Petersen
    Ribeiro, Mauricio Alves
    Szutan, Luiz Arnaldo
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2020, 66 (03): : 275 - 283
  • [22] Biomarkers of Apoptosis and Necrosis in Patients with Hepatocellular Carcinoma Treated with Sorafenib
    Godin, Corinne
    Louandre, Christophe
    Bodeau, Sandra
    Diouf, Momar
    Saidak, Zuzana
    Conte, Marie-Alix
    Chauffert, Bruno
    Barbare, Jean-Claude
    Barget, Nathalie
    Trinchet, Jean-Claude
    Ganne, Nathalie
    Galmiche, Antoine
    ANTICANCER RESEARCH, 2015, 35 (03) : 1803 - 1808
  • [23] Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression
    Apostolidis, Leonidas
    Pfeiffenberger, Jan
    Gotthardt, Daniel
    Radeleff, Boris
    Mehrabi, Arianeb
    Schemmer, Peter
    Jaeger, Dirk
    Schirmacher, Peter
    Stremmel, Wolfgang
    Schulze-Bergkamen, Henning
    Springfeld, Christoph
    Weiss, Karl Heinz
    GASTROINTESTINAL TUMORS, 2018, 5 (1-2) : 38 - 46
  • [24] Predictors of time to progression in patients treated with sorafenib for hepatocellular carcinoma
    Salimi, S.
    Mudaliar, S.
    Davison, S.
    Shackel, N.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 92 - 93
  • [25] LEVOCARNITINE INHIBITS PRESARCOPENIA IN PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH SORAFENIB
    Nagai, Hidenari
    Amanuma, Makoto
    Mukozu, Takanori
    Kobayashi, Kojiro
    Watanabe, Go
    Ogino, Yu
    Matsui, Teppei
    Daido, Yasuko
    Wakui, Noritaka
    Momiyama, Koichi
    Igarashi, Yoshinori
    HEPATOLOGY, 2021, 74 : 654A - 655A
  • [26] Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib
    Sansone, Vito
    Tovoli, Francesco
    Casadei-Gardini, Andrea
    Di Costanzo, Giovan Giuseppe
    Magini, Giulia
    Sacco, Rodolfo
    Pressiani, Tiziana
    Trevisani, Franco
    Rimini, Margherita
    Tortora, Raffaella
    Nardi, Elena
    Ielasi, Luca
    Piscaglia, Fabio
    Granito, Alessandro
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2021, 12 (01)
  • [27] Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib
    Ozenne, Violaine
    Paradis, Valerie
    Pernot, Simon
    Castelnau, Corinne
    Vullierme, Marie-Pierre
    Bouattour, Mohamed
    Valla, Dominique
    Farges, Olivier
    Degos, Francoise
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2010, 22 (09) : 1106 - 1110
  • [28] The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib
    Chen, Lufeng
    Su, Hongying
    Shao, Haibo
    Xu, Ke
    Liang, Songnian
    Liu, Ling
    HEPATO-GASTROENTEROLOGY, 2014, 61 (131) : 802 - 808
  • [29] Impact of Pretreatment Serum Cholinesterase Level in Unresectable Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib
    Takeda, Haruhiko
    Nishikawa, Hiroki
    Sakamoto, Azusa
    Nasu, Akihiro
    Kita, Ryuichi
    Kimura, Toru
    Osaki, Yukio
    HEPATOLOGY, 2012, 56 : 469A - 470A
  • [30] Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib
    Labenz, Christian
    Prenosil, Vera
    Koch, Sandra
    Huber, Yvonne
    Marquardt, Jens U.
    Schattenberg, Joern M.
    Galle, Peter R.
    Weinmann, Arndt
    Woerns, Marcus-Alexander
    DIGESTIVE DISEASES, 2017, 36 (01) : 78 - 88
12345